ReviewDermatology and therapy2025
Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative Review.
Review in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- IL-36-Driven Inflammation in Generalized Pustular Psoriasis: Immunological Insights from Plaque Psoriasis and Implications for Targeted Therapy.International journal of molecular sciences · 2026Review
- Breaking the barrier: oral tacrolimus plus apremilast rescues acute generalized pustular psoriasis with severe comorbidities-a case report.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Generalized pustular psoriasis (GPP) is a rare, chronic dermatological condition characterized by widespread pustulation that may be associated with other cutaneous and systemic manifestations. If left untreated, it may be life-threatening. Therapies developed for plaque psoriasis have been used to treat GPP with limited efficacy; however, these therapies do not target the interleukin (IL)-36 pathway, which is the most common pathway implicated in the pathogenesis of GPP. A systemic biologic targeting the IL-36 receptor for the treatment of GPP is currently the only approved treatment for GPP and allows for an opportunity to improve patient outcomes. This manuscript outlines practical considerations that aim to provide guidance on personalizing the treatment of GPP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.